Activated TGFBR1 cannot phosphorylate SMAD2 and SMAD3 Phosphorylation Motif Mutants

Stable Identifier
R-HSA-3304394
Type
Reaction [transition]
Species
Homo sapiens
Compartment
early endosome membrane
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Activated TGFBR1 cannot phosphorylate SMAD2 and SMAD3 Phosphorylation Motif Mutants
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

SMAD2 and SMAD3 phosphorylation motif mutants cannot be phosphorylated and activated by the TGF-beta receptor complex (Fleming et al. 2013), in contrast to the wild-type SMAD2 and SMAD3 (Souchelnytskyi et al. 2001).

SMAD2 phosphorylation motif mutant SMAD2 S464*, which lacks the phosphorylation motif, has been annotated as a characterized member of the mutant set (Fleming et al. 2013), while SMAD2 S464L, SMAD S467P and SMAD3 S425C are candidate mutant set members. In addition, the following SMAD2 and SMAD3 truncation mutants that lack various portions of the MH2 domain, including phosphorylation sites, are annotated as candidate loss-of-function mutants:
SMAD2 S296*
SMAD2 S306*
SMAD2 S308*
SMAD2 L315*
SMAD2 R321*
SMAD2 W422*
SMAD2 R427*
SMAD2 Q429*
SMAD2 E439*
SMAD2 W448*
SMAD2 Q455*
SMAD2 C463*
SMAD3 E246*
SMAD3 Y298*
SMAD3 Q316*
SMAD3 Q322*
SMAD3 W326*
SMAD3 Q358*
SMAD3 R368*
SMAD3 E383*
SMAD3 Y384*

As SMAD2 and SMAD3 phosphorylation motif missense mutants (Fleming et al. 2013) have all the MH2 domain residues involved in ZFYVE9 (SARA)-mediated recruitment of SMAD2/3 to activated TGF-beta receptor complex 1 (TGFBR1) (Wu et al. 2000) intact, it is assumed that SMAD2/3 phosphorylation mutants bind phosphorylated TGFBR1. This has not been experimentally examined. It is likely that at least some of the nonsense SMAD2 and SMAD3 mutants, which lack parts of the MH2 domain, are unable to bind to ZFYVE9.

Literature References
PubMed ID Title Journal Year
23139211 SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer

Mouradov, D, Jorissen, RN, Jones, IT, Tsui, C, Palmieri, M, Sieber, OM, Ward, RL, Fleming, NI, Mariadason, JM, Sakthianandeswaren, A, Lipton, L, Moore, J, Ruszkiewicz, AR, Busam, D, Christie, M, McLaughlin, S, Gibbs, P, Zhu, HJ, Strausberg, RL, Day, F, Li, S, Burgess, AW, Hawkins, NJ, Desai, J, Zhao, Q

Cancer Res. 2013
11100470 Phosphorylation of Smad signaling proteins by receptor serine/threonine kinases

Souchelnytskyi, S, ten Dijke, P, Heldin, CH, Rönnstrand, L

Methods Mol Biol 2001
Participants
Input
Participates
as an event of
Normal reaction
Activated type I receptor phosphorylates SMAD2/3 directly (Homo sapiens)
Functional status

Loss of function of TGFB1:p-TGFBR:ZFYVE9:SMAD2/3 Phosphorylation Motif Mutants [early endosome membrane]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2013-08-08)
Akhurst, RJ  (2013-08-08)
Meyer, S  (2013-08-08)
Reviewed
Akhurst, RJ  (2013-08-08)
Meyer, S  (2013-08-08)
Created
Orlic-Milacic, M  (2013-04-24)
Cite Us!